Bisphosphonate drug holiday: who, when and how long
“The four nitrogen-containing bisphosphonates currently in clinical use for the treatment of osteoporosis differ in the strength for binding to bone. The rank order for binding affinity is zoledronate > alendronate > ibandronate > risedronate [Russell et al. 2008]. Higher-affinity bisphosphonates will bind avidly to the bone surface but will spread through bone more slowly, while lower-affinity agents will be distributed more widely through the bone but have a shorter residence time in bone if treatment is stopped. These agents also differ in the potency for inhibiting farnesyl pyrophosphate synthase. The rank order of potency for inhibiting this enzyme is zoledronate > risedronate >> ibandronate > alendronate [Russell et al. 2008]. Bisphosphonate use results in a rapid and substantial decrease in bone turnover markers that is dose and compound dependent, with a maximum effect in 3–6 months. This effect is maintained in a new steady state for at least 10 years with continued treatment [Bone *et al.*2004].“
“In conclusion, bisphosphonates that have been approved for the treatment of postmenopausal osteoporosis are effective and generally safe agents that have robust evidence for fracture risk reduction. Their systemic safety is related to their binding to bone and lack of uptake by other tissues other than the kidney. A reservoir of bisphosphonates accumulates after years of treatment that is gradually released over months or years and appears to result in a lingering antifracture benefit for some time after therapy is stopped.“